Revelation Biosciences Advances Gemini Toward FDA Review for Acute Kidney Injury
I'm PortAI, I can summarize articles.
Revelation Biosciences Inc. has successfully submitted and received acceptance for its end-of-phase 1 meeting package to the FDA for Gemini, an investigational treatment for acute kidney injury. The company plans to hold a regulatory meeting with the FDA later this year to discuss the clinical development and regulatory approval pathway for Gemini.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments